Videos

Experts discuss discuss the American College of Radiology recommendations regarding the use of contrast media and their guidance related to the use of generics during supply shortages.

Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, discuss generic agents iodixanol injection and gadoterate meglumine injection for the use in imaging modalities.

Experts discuss the concept of generics and how they have traditionally been utilized in the healthcare space.

Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, provide an overview of the different imaging technique protocols needed for contrast agents.

In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.

Radiology experts discuss the role of contrast agents in imaging and the impact these agents have on image quality.

Joseph Cavallo, MD, MBA, and Dushyant Sahani, MD, provide a brief overview of imaging modalities and their importance in medical diagnosis and treatment.

In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.

In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.

In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.

In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.

The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?

In an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Jeremie Calais, M.D., MSc discussed promising research findings for the use of the positron emission tomography (PET) imaging agent 89ZR-DFO-girentuximab for diagnosing clear cell renal cell carcinoma.

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.

In a recent video interview from the Society for Imaging Informatics in Medicine (SIIM) conference, Ali Tejani, M.D., discussed pertinent insights on leveraging the value of adjunctive artificial intelligence (AI)-enabled triage software for computed tomography (CT) scans with radiology workflow improvements to achieve “clinically meaningful change” for patients with incidental pulmonary emboli findings.

In a recent video interview, Stephen Rose, M.D., reviewed a variety of factors that can impact interpretation of breast imaging for women with breast implants and discussed recent research showing a 22 percent reduction in cancer detection rate for this population in comparison to women without breast implants.

In a recent interview, Rajesh Bhayana, M.D., shared insights from new research that compared the abilities of ChatGPT-3.5 and ChatGPT-4 to answer text-based questions akin to those found on a radiology board examination.

In a recent video interview, David Ouyang, M.D., shared insights from two recent studies he co-authored on the use of artificial intelligence (AI) to improve initial assessment of left ventricular ejection fraction (LVEF) on echocardiography and ascertain cardiac risks associated with changes in the left ventricle sphericity index seen on magnetic resonance imaging (MRI).

In a recent video interview from the American Urological Association (AUA) 2023 Annual Meeting, Brian Helfand, M.D., discussed emerging research that shows the potential viability of the agent F18-rhPSMA-7.3 for enhancing the detection of prostate cancer recurrence and facilitating earlier intervention for patients with low prostate-specific antigen (PSA) levels.

In recent video interviews, Tessa Cook, MD, PhD, Nina Kottler, MD, MS, and Sonia Gupta, MD shared their insights and perspective on potential benefits and drawbacks of ChatGPT in radiology.

In a recent video interview, Amy Patel, M.D., shared her perspective on forthcoming national beast density notification in mammography reporting, emphasized the importance of educating primary care providers on breast density risks, and discussed the ongoing need for coverage of supplemental options for breast cancer screening.

In a recent video interview, Emily Conant, M.D., discussed findings from a large multicenter study highlighting the benefits of digital breast tomosynthesis (DBT) in breast cancer screening.

In a recent video interview, Wendie Berg, M.D., Ph.D., discussed the newly issued final rule from the Food and Drug Administration (FDA) requiring a national standard for breast density notification (starting on September 10, 2024) as well as its potential impact in mammography reporting and facilitating supplemental screening for patients with dense breasts.

In a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, Brian Chapin, MD, discussed emerging research that demonstrated the ability of the positron emission tomography (PET) agent 18F-rhPSMA-7.3 to diagnose distant M1 lesions prior to surgery for patients with intermediate to high-risk prostate cancer.

In a recent video interview, radiologist Jonathon Lee, MD, shared insights from his experience on the insidious nature of burnout, emphasized the link between work-life balance and productivity, and discussed a recent partnership between the teleradiology service provider vRad and the behavioral health consultancy VITAL WorkLife to help promote well-being for vRad teleradiologists.

In a recent video interview, Sonia Gupta, MD discussed a number of ongoing developments with artificial intelligence (AI) in radiology, ranging from market consolidation of AI vendors to maximizing automation and efficiency with patient triage, reporting and follow-up of incidental findings.

In a video interview at the recent Radiological Society of North America (RSNA) conference, Wayne Dell, M.D., discussed retrospective research that examined the use of hyperlinked multimedia radiology reports across modality and subspecialty five years after initial implementation of the technology at the University of Virginia.

In a recent video interview, Amar Kishan, M.D., discussed a new study that demonstrated significant side effect reduction when utilizing magnetic resonance imaging (MRI) guidance instead of computed tomography (CT) guidance for stereotactic body radiation therapy (SBRT) to treat localized prostate cancer.